Lexeo Therapeutics announced updates to key components of an Accelerated Approval pathway for LX2006 in Friedreich ataxia (FA) cardiomyopathy and new interim clinical data from their ongoing Phase I/II studies. Read their letter to the FA community at Pharma News - National Ataxia Foundation.
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Trials of LX2006 for the treatment of Friedreichs Ataxia Cardiomyopathy | 0 | 149 | June 19, 2023 | |
| Friedreich's Ataxia Symposium at The Children's Hospital of Philadelphia | 0 | 1848 | January 12, 2015 | |
| Friedreich Ataxia - Pipeline Review | 0 | 1877 | April 19, 2017 | |
| Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Friedreich’s Ataxia | 0 | 1704 | June 23, 2017 | |
| Potential Gene Therapies for Friedreichs Ataxia | 1 | 342 | August 1, 2019 |